Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Novel Catheter Mimics Snake Teeth to Grab Blood Clots

By HospiMedica International staff writers
Posted on 19 Feb 2025

Stroke is the second leading cause of death worldwide, claiming approximately 140,000 lives in the United States each year. More...

Nearly 90% of stroke cases are ischemic strokes, caused by blockages in the arteries that supply blood to the brain. Stroke is a highly time-sensitive condition that demands rapid intervention for the best possible recovery. Traditional stent retrievers, which are used to remove clots, often cause higher rates of vessel perforation due to the interaction between the metal struts and the vessel walls. This can lead to intracranial hemorrhages, which occur at a higher rate than with aspiration catheters, which use suction through a tube. These hemorrhages can be asymptomatic or symptomatic, but no physician is comfortable causing any damage to the patient's blood vessels. To address this issue, researchers have developed a novel extraction device that mimics a snake’s evolutionary advantage to improve the retrieval of blood clots in the brain.

Emboa Medical (West Lafayette, IN, USA) has developed a novel microstructured catheter designed to improve outcomes for stroke patients. The company’s patent-pending platform, known as TRAP (thrombus retrieval aspiration platform), emulates the arrangement of a boa constrictor’s teeth in its biomimetic design, allowing it to grasp blood clots without damaging them. The TRAP catheter demonstrated over a 200% increase in the force used to remove blockages compared to traditional catheters. Additionally, it showed significant benefits in removing clots on the first attempt in a worst-case neurovascular model, achieving a 40% success rate compared to just 10% with conventional smooth inner diameter catheters.

Emboa has been working diligently to refine the design of the microstructures using physiologically relevant models to further distinguish its catheter from others currently available on the market. The company has conducted in vitro experiments that provide quantitative evidence of the advantages of TRAP catheters. Moreover, Emboa plans to carry out an in vivo porcine model study, aiming to preliminarily validate the safety and effectiveness of TRAP by the end of Q1 2025. The successful completion of this animal model study will pave the way for developing more functional and robust TRAP devices, facilitating the transition to larger-scale verification activities and eventual regulatory approval. Another key step in bringing TRAP to market is establishing a manufacturing process that will integrate these microscale structures into the distal tip of the catheters.

Related Links:
Emboa Medical


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
Digital Color Doppler Ultrasound System
MS22Plus
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.